Johnson & Johnson posted $14.96 billion in U.S. sales for the third quarter.
Sentimentneutral 50
Neutral · 50 of 100
Impact30
low · stays off the top drivers
Confidence80%
high confidence · single wire
Eventdeveloping
v1 · alerted to followers
FREE ACCOUNT · NO CARD
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
WHY IT MATTERS••••••••••Market transmission and exposed assetsBULL / BEAR CASE•••• / ••••Competing evidence, edited togetherNEWS ON PRICE••.•% reactionConfirmation versus SPY and sectorWHAT TO WATCH•• catalystsThe facts that can change the read
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
J&J Falls 4% as Medtech Sales Miss, Plans Orthopedics Spinoff in 2027bearish 30 · impact 70
Johnson & Johnson Falls After Q3 Revenue Miss, Medtech Sales Hit by Middle East Conflictbearish 30 · impact 60
Johnson & Johnson reports Q3 sales growth, raises 2026 guidancebullish 70 · impact 60
Johnson & Johnson beats Q3, raises guidance, but MedTech miss sends stock lowerbearish 35 · impact 40
Johnson & Johnson lifts full-year guidance after Q3 momentumbullish 80 · impact 60
Johnson & Johnson Q3 EPS 9 cents on $5.5B talc litigation chargebearish 30 · impact 60
Johnson & Johnson beats Q3 estimates, raises guidance; MedTech miss weighs on sharesbearish 35 · impact 40
Johnson & Johnson MedTech sales miss across all four businessesbearish 35 · impact 40
J&J medical device sales miss Q3 estimates, pharma beatsbearish 35 · impact 40
Johnson & Johnson Q3 beats EPS estimates, raises full-year guidancebullish 70 · impact 60
Johnson & Johnson Q3 beats estimates, lifts full-year outlookbullish 70 · impact 70
Johnson & Johnson Q3 adjusted EPS beats estimates, raises FY guidancebullish 70 · impact 60
Johnson & Johnson 3Q MedTech Sales $8.64Bneutral 50 · impact 30
Johnson & Johnson Third-Quarter EPS 9 Centsbearish 40 · impact 20
Johnson & Johnson Third-Quarter U.S. Sales Hit $14.96 Billionneutral 50 · impact 30 · this page
Johnson & Johnson third-quarter sales $25.4 billionneutral 50 · impact 40
Johnson & Johnson reports Q3 2026 results, raises 2026 guidancebullish 70 · impact 70
JNJ Q3 Innovative Medicine Sales Hit $16.76Bneutral 50 · impact 20
Johnson & Johnson reports Q3 2026 results, lifts 2026 guidanceneutral 50 · impact 60
Johnson & Johnson Reports 3Q Adjusted EPS of $2.59neutral 50 · impact 60 · first wire
Where this story sitsringed dot is this story
bullishneutralbearishlabel = ticker sentiment·impact · dot size follows impact · click a dot to open the story
Every story, completefree account
A free account opens the reasons behind every story, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone, plus 3 complete ticker and report views a day. BORSA Plus removes the daily limit and adds alerts on your names.
BORSA uses AI-assisted classification and synthesis with deterministic event controls. Market sentiment is informational and is not individualized investment advice.
